Lymphatic system neoplasms treatment: prognostic factors

About the authors

D V Kharazishvili

I A Vorobyev

References

  1. Smithers D. W. Summary of papers delivered at the Conference on Staging in Hodgkin's Disease (Ann Arbor). Cancer Res. 1971;31:1869-1870.
  2. Rai K. R., Sawitsky A., Cronkite E. P. et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
  3. Binet J. L., Auqer A., Dighiero G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from multivariant survival analysis. Cancer (Philad.) 1981; 48: 198-206. -29
  4. Shipp M. A., Harrington D. P., Anderson J. R. et al. A predictive mode! for agressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329: 987- 994.
  5. Connors J. M., Ktimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin. Hematol. 1988; 25: 41-46.
  6. Longo D. L., De Vita V. Т., Duffey P. L. et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment advanced diffuse aggressive lymphoma: Results of prospective randomized trial. J. Clin. Oncol. 1991; 9: 25-38.
  7. Fisher R. L., Gaynor E., Dahlberg S. et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002-1006.
  8. Meyer R. M., Quirt I. C, Skillings J. R. et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. Ibid. 329: 1770-1776.
  9. Diehl V., Franklin J., Paulus U. et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. In: Program and abstracts of the 43rd Annual Meeting of American Society of Hematology. Orlando, Florida; 2001. Abstr. 3202.
  10. Skipper H. E., Schabel F. M., Wilcox W. S. Experimental evaluation of potential anti-cancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia, Cancer Chemother. Rep. 1964; 35: 1-12.
  11. De Vita V. T. Principles of cancer management: Chemotherapy. In: De Vita Jr., Hellman S., Rosenberg S. A., eds. Cancer: Principles and practice of oncology. 5nd ed. Philadelphia: Lippincot-Raven Publishers; 1997. 333-347.
  12. Norton L. A. A Gompertzian model of human breast cancer growth. Cancer Res. 1988; 48: 7067-7071.
  13. De Vita V. T. The influence of information on drug resistance on protocol design: The Harry Kaplan Memorial Lecture given at the Fourth International Conference on Malignant Lymphoma. Ann. Oncol. 1991; 2: 93-112.
  14. Shenkier T. N., Voss N., Fairey R. et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse largecell lymphoma: An 18-year experience from the British Columbia Cancer Agency. J. Clin. Oncol. 2002; 20: 197-204.
  15. Goldie J. H., Goldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 1979; 63: 1727-1733.
  16. Воробьев А. И. Опухолевая прогрессия и некоторые вопросы патогенеза лейкозов: Автореф. дис... д-ра мед. наук. М.; 1968.
  17. Armitage J. О., Weisenburger D. D., Hutchins M. et al. Chemotherapy for diffuse large-cell lymphoma - rapidly responding patients have more durable remissions. J. Clin. Oncol. 1986; 4: 160-164.
  18. Verdonck L. F., van Putten W. L., Hagenbeek A. et al. Comparison of CHOP chemotherapy with autologus bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1995; 332: 1045- 1051.
  19. Rai K., Peterson B. L., Appelbaum F. R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. Ibid. 2000; 343: 1750-1757.
  20. Kimby E., Brandt L., Nygren P. et al. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncol. 2001; 40: 224-230.
  21. Robak T. The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia - lessons learned from prospective randomized trials. Leukemia and Lymphoma 2002; 43: 537-548.
  22. Воробьев А. И. (ред.) Руководство по гематологии. М.: Медицина; 1985.
  23. Drillenburg P., Pals S. Т. Cell adhesion receptors in lymphoma dissemination. Blood 2000; 95: 1900-1910.
  24. Giles F. J., O'Brien S. M., Keating M. J. Chronic lymphocytic leukemia in (Richter's) transformation. Semin. Oncol. 1998; 25: 117-125.
  25. Jonson S. A., Thomas W. Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies. Hematol. Oncol. 2000; 18: 141-153.

Statistics

Views

Abstract - 60

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Kharazishvili D.V., Vorobyev I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies